United Microelectronics Corporation (UMC)
NYSE: UMC · Real-Time Price · USD
6.67
-0.07 (-1.04%)
At close: Aug 7, 2025, 4:00 PM
6.68
+0.01 (0.15%)
Pre-market: Aug 8, 2025, 5:18 AM EDT
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Blueprint Medicines stock has a target of 7.40, which predicts a 10.94% increase from the current stock price of 6.67.
Price Target: $7.40 (+10.94%)
Analyst Consensus: Sell
* Price targets were last updated on Oct 17, 2024.
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy → Strong Sell Downgrades n/a | Strong Buy → Strong Sell | Downgrades | n/a | n/a | Jan 21, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 30, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 28, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $7.4 | Strong Buy → Hold | Downgrades | $7.4 | +10.94% | Oct 17, 2024 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades n/a | Hold → Strong Buy | Upgrades | n/a | n/a | Apr 24, 2024 |
Financial Forecast
Revenue This Year
250.34B
from 232.30B
Increased by 7.77%
Revenue Next Year
265.83B
from 250.34B
Increased by 6.19%
EPS This Year
3.53
from 3.74
Decreased by -5.62%
EPS Next Year
4.11
from 3.53
Increased by 16.48%
Financial currency is TWD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 301.2B | 316.8B | 323.3B | ||
| Avg | 250.3B | 265.8B | 283.5B | ||
| Low | 223.6B | 223.3B | 231.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 29.7% | 26.5% | 21.6% | ||
| Avg | 7.8% | 6.2% | 6.6% | ||
| Low | -3.7% | -10.8% | -12.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.27 | 5.55 | 5.17 | ||
| Avg | 3.53 | 4.11 | 4.70 | ||
| Low | 2.75 | 3.12 | 4.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.3% | 57.2% | 25.6% | ||
| Avg | -5.6% | 16.5% | 14.4% | ||
| Low | -26.4% | -11.7% | 3.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.